Finally, using the pharmacological inhibitors of P-glycoprotein (elacridar) and NFκB (PDTC), we observed that the resistance conferred by the drug efflux pump, but not NFκB activation, is reversible, and it can eliminate a leukemia cell model with the activation of both of the molecular processes (Figure 8). This evidence concerns the gene NFKB1 and leukemia.